xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05970016</url>
    </required_header>
    <id_info>
      <org_study_id>TCC1727-101</org_study_id>
      <nct_id>NCT05970016</nct_id>
    </id_info>
    <brief_title>A Phase I/II Clinical Study in Patients With Advanced Solid Tumor.</brief_title>
    <official_title>A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TCC1727 Tablets in Patients With Advanced Solid Tumor.</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Beijing Tide Pharmaceutical Co., Ltd</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Beijing Tide Pharmaceutical Co., Ltd</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety,&#xD;
        PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The study will be divided into two stages: the first stage is a phase I dose finding study in&#xD;
        patients with advanced solid tumors; the second stage is a phase II cohort expansion study.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 7, 2023</start_date>
    <completion_date type="Anticipated">September 30, 2025</completion_date>
    <primary_completion_date type="Anticipated">March 30, 2025</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Phase I: To determine dose-limiting toxicity (DLT) at each dose level and identify MTD and RP2D.</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation To observe the tolerability and safety of TCC1727 tablets and determine the maximum-tolerated dose (MTD) and the recommended phase II dose (RP2D) of TCC1727 tablets when administered orally once a day (QD) in 21-day cycle in patients with advanced solid tumors.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Phase II: To evaluate the preliminary efficacy of TCC1727 tablets as measured by ORR in patients with advanced solid tumors with DNA damage response (DDR) defects</measure>
      <time_frame>6 months</time_frame>
      <description>Phase II: Cohort Expansion ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009) for each tumor type. The overall response rate is defined as proportion of subjects who had the best overall response (BOR) of complete response (CR) or partial response (PR).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Phase I: Dose Escalation To observe the preliminary efficacy of TCC1727 tablets as measured by overall response rate (ORR) in patients with advanced solid tumors.</measure>
      <time_frame>6 months</time_frame>
      <description>To evaluate the preliminary efficacy by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression free survival (PFS) and overall survival (OS).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I: To evaluate the pharmacokinetic (PK) of TCC1727 tablets in patients with advanced solid tumors</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: Tmax</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I:</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: Cmax</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I:</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: t1/2</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I:</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: AUC0-t,</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I:</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: Cmax,ss</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I:</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: AUCtau,ss,</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase I:</measure>
      <time_frame>21 days</time_frame>
      <description>Phase I: Dose Escalation Pharmacokinetic parameters: Cmin,ss</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase II: To evaluate the safety and tolerability of TCC1727 tablets in patients with advanced solid tumors with DDR defects</measure>
      <time_frame>6 months</time_frame>
      <description>Phase II: Cohort Expansion Assessment of all AEs, SAEs and TEAEs;</description>
    </secondary_outcome>
    <number_of_arms>7</number_of_arms>
    <enrollment type="Anticipated">40</enrollment>
    <condition>Patients With Advanced Solid Tumors</condition>
    <arm_group>
      <arm_group_label>5mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>10mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>20mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>40mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>60mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>80mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>100mg treatment group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Administered orally once a day (QD)</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>TCC1727 tablet</intervention_name>
      <description>TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.</description>
      <arm_group_label>100mg treatment group</arm_group_label>
      <arm_group_label>10mg treatment group</arm_group_label>
      <arm_group_label>20mg treatment group</arm_group_label>
      <arm_group_label>40mg treatment group</arm_group_label>
      <arm_group_label>5mg treatment group</arm_group_label>
      <arm_group_label>60mg treatment group</arm_group_label>
      <arm_group_label>80mg treatment group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Male or female subjects who have provided voluntary informed consent for participation&#xD;
               in the study and to follow the protocol requirements&#xD;
  &#xD;
            2. Male or female subjects 18-70 years of age&#xD;
  &#xD;
            3. Subjects with histologically or cytologically confirmed malignant advanced solid&#xD;
               tumors who have progressed on (or have not been able to tolerate) standard therapy or&#xD;
               for whom no suitable effective standard therapy exists&#xD;
  &#xD;
                 1. For Phase I, all tumor types will be enrolled&#xD;
  &#xD;
                 2. For Phase II, Patients with DDR defects detection at central laboratory will be&#xD;
                    enrolled&#xD;
  &#xD;
            4. Subject with at least one measurable lesion according to RECIST criteria (version 1.1)&#xD;
               for solid tumors will be allowed to include in phase II (if there is no measurable&#xD;
               lesion but there are assessable lesions then the subject will be allowed to be&#xD;
               included after the judgment of the investigator in phase I only)&#xD;
  &#xD;
            5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
  &#xD;
            6. Subjects with life expectancy of ≥12 weeks&#xD;
  &#xD;
            7. Subjects 12-lead ECG evaluation of QT level using Fridericia formula (QTcF) &lt; 450 mse&#xD;
  &#xD;
            8. Subjects must have the following laboratory values:&#xD;
  &#xD;
                 1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;&#xD;
  &#xD;
                 2. Platelet count (PLT) ≥ 100 × 109/L;&#xD;
  &#xD;
                 3. Hemoglobin (HB) ≥ 9.0 g/L;&#xD;
  &#xD;
                 4. No blood transfusion or hematopoietic stimulating factor treatment within 14&#xD;
                    days;&#xD;
  &#xD;
                 5. Bilirubin total ≤ 1.5 times the upper limit of normal (ULN);&#xD;
  &#xD;
                 6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (In&#xD;
                    case of liver metastasis, ALT and AST ≤ 5 × ULN);&#xD;
  &#xD;
                 7. 24-hour or calculated creatinine clearance (CrCl) ≥ 60 mL/min (according to&#xD;
                    Cockcroft-Gault formula)*, or the 24-hour creatinine clearance measured in urine&#xD;
                    is ≥ 50 mL/min, the patient will still be selected. *For CrCl value, the&#xD;
                    eligibility should be determined using the Cockcroft-Gault formula:&#xD;
  &#xD;
                      -  Male CrCl (mL/min) = body weight (kg) × (140 - age)/[72 × serum creatinine&#xD;
                         (mg/dL)]&#xD;
  &#xD;
                      -  Female CrCl (mL/min) = male CrCl × 0.85&#xD;
  &#xD;
                 8. International normalized ratio (INR) ≤ 1.5 × ULN, Activated partial&#xD;
                    thromboplastin time (APTT) ≤ 1.5 × ULN;&#xD;
  &#xD;
            9. Women of childbearing potential agreed to use effective contraceptives during the&#xD;
               study treatment period and within 3 months after the end of the study treatment&#xD;
               period.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          Subjects will be excluded from the study based on the following criteria:&#xD;
  &#xD;
            1. Imaging examination suggests intracranial metastasis, which requires local treatment&#xD;
               (in case of asymptomatic or symptomatic brain metastasis requiring no local treatment&#xD;
               based on the investigator's judgement, the subject can still be included), or&#xD;
               currently taking steroid hormone prior to inclusion, such as &gt;10 mg prednisone (or&#xD;
               equivalent) for intracerebral edema from brain metastases; subjects with meningeal&#xD;
               carcinomatosis will be excluded regardless of their clinical stability&#xD;
  &#xD;
            2. History of previously received major surgery or surgical therapy for any cause within&#xD;
               4 weeks of the first dose; radiotherapy, chemotherapy, other clinical trial drugs or&#xD;
               other anti-tumor treatment, within 5 half-lives or 3 weeks (whichever is shorter),&#xD;
               prior administering the first dose of study drug on Day 1&#xD;
  &#xD;
            3. History of previous treatment with ATR inhibitors or other DDR related inhibitors&#xD;
               (except poly ADP ribose polymerase enzyme (PARP) inhibitors)&#xD;
  &#xD;
            4. Subjects with a history of another primary malignancy other than:&#xD;
  &#xD;
                 1. carcinomas in situ, (e.g., breast, cervix, and prostate)&#xD;
  &#xD;
                 2. Locally excised non-melanoma skin cancer&#xD;
  &#xD;
                 3. No evidence of disease from another primary cancer for two or more years and has&#xD;
                    not taken any anti-cancer treatment in two years. Exceptions are&#xD;
                    gonadotropin-releasing hormone (GnRH) therapy for prostate cancer and hormonal&#xD;
                    maintenance therapy for breast cancer.&#xD;
  &#xD;
            5. Previously received treatment with strong CYP3A4, CYP2C8 and P-gp inhibitors or strong&#xD;
               CYP3A4, CYP2C8 and P-gp inducers within 14 days prior to the first medication&#xD;
  &#xD;
            6. Patients with AE due to previous anti-tumor treatment that has not recovered to ≤&#xD;
               CTCAE grade 1 (except for alopecia, pigmentation and lymphopenia)&#xD;
  &#xD;
            7. Patients who are unable to swallow the tablets normally, or have abnormal&#xD;
               gastrointestinal function that may affect the drug absorption, such as malabsorption&#xD;
               syndrome or major resection of the stomach or bowels based on the judgment of the&#xD;
               investigator&#xD;
  &#xD;
            8. Subjects with any severe and/or uncontrolled disease, including:&#xD;
  &#xD;
                 1. Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic&#xD;
                    blood pressure ≥ 100 mmHg)&#xD;
  &#xD;
                 2. Myocardial infarction, arrhythmia (CTCAE grade 2 and above, also including ≥&#xD;
                    Class II congestive heart failure (CHF) (New York Heart Association (NYHA)&#xD;
                    classification) (refer to Appendix-A)&#xD;
  &#xD;
                 3. Active infection or fever of unknown origin ≥ 38.5℃ within 7 days prior to the&#xD;
                    first medication&#xD;
  &#xD;
                 4. Active viral hepatitis; positive hepatitis B surface antigen and/or hepatitis B&#xD;
                    core antibody and measured HBV DNA value ≥ 500 IU/ml; positive HCV antibody and&#xD;
                    measured HCV titer exceeding the upper limit of normal;&#xD;
  &#xD;
                 5. Positive Treponema pallidum antibody;&#xD;
  &#xD;
                 6. History of immunodeficiency, including positive HIV antibody or other acquired or&#xD;
                    congenital immunodeficiency diseases, or history of organ transplant;&#xD;
  &#xD;
                 7. Poor control of diabetes (fasting blood glucose (FBG) &gt; 10 mmol/L);&#xD;
  &#xD;
                 8. Liver disease such as decompensated liver disease&#xD;
  &#xD;
            9. Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion as per the&#xD;
               investigator opinion&#xD;
  &#xD;
           10. Patients with clinically significant hemorrhage symptoms or bleeding tendency within 3&#xD;
               months prior to the first study medication&#xD;
  &#xD;
           11. Known hypersensitivity or contraindication to any drug or any of the components of&#xD;
               investigational product&#xD;
  &#xD;
           12. Any other clinically significant acute or chronic medical or psychiatric or any&#xD;
               laboratory abnormality that may increase the risk associated with study drug&#xD;
               administration or may interfere with the interpretation of study results&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>70 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Lingying Wu, PHD</last_name>
      <phone>86-01-87788996</phone>
      <email>wulingying@csco.org.cn</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Guangwen Yuan, PHD</last_name>
      <phone>86-01-87788996</phone>
      <email>william327@126.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
        <address>
          <city>Beijing</city>
          <state>No.17, Panjiayuan Nanli, Chaoyang District, Beijing</state>
          <country>China</country>
        </address>
      </facility>
      <contact>
        <last_name>Lingying Wu, PHD</last_name>
        <phone>86-01-87788996</phone>
        <email>wulingying@csco.org.cn</email>
      </contact>
      <contact_backup>
        <last_name>Guangwen Yuan</last_name>
        <phone>86-01-87788996</phone>
        <email>william327@126.com</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>China</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 14, 2023</study_first_submitted>
    <study_first_submitted_qc>July 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 1, 2023</study_first_posted>
    <last_update_submitted>July 23, 2023</last_update_submitted>
    <last_update_submitted_qc>July 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 1, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05970016
  org study id: TCC1727-101
  nct id: NCT05970016
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety,
        PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.
  The study will be divided into two stages: the first stage is a phase I dose finding study in
        patients with advanced solid tumors; the second stage is a phase II cohort expansion study.
  allocation: Non-Randomized
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Phase I: To determine dose-limiting toxicity (DLT) at each dose level and identify MTD and RP2D.
  time frame: 21 days
  description: Phase I: Dose Escalation To observe the tolerability and safety of TCC1727 tablets and determine the maximum-tolerated dose (MTD) and the recommended phase II dose (RP2D) of TCC1727 tablets when administered orally once a day (QD) in 21-day cycle in patients with advanced solid tumors.
  measure: Phase II: To evaluate the preliminary efficacy of TCC1727 tablets as measured by ORR in patients with advanced solid tumors with DNA damage response (DDR) defects
  time frame: 6 months
  description: Phase II: Cohort Expansion ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009) for each tumor type. The overall response rate is defined as proportion of subjects who had the best overall response (BOR) of complete response (CR) or partial response (PR).
  measure: Phase I: Dose Escalation To observe the preliminary efficacy of TCC1727 tablets as measured by overall response rate (ORR) in patients with advanced solid tumors.
  time frame: 6 months
  description: To evaluate the preliminary efficacy by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression free survival (PFS) and overall survival (OS).
  measure: Phase I: To evaluate the pharmacokinetic (PK) of TCC1727 tablets in patients with advanced solid tumors
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: Tmax
  measure: Phase I:
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: Cmax
  measure: Phase I:
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: t1/2
  measure: Phase I:
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: AUC0-t,
  measure: Phase I:
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: Cmax,ss
  measure: Phase I:
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: AUCtau,ss,
  measure: Phase I:
  time frame: 21 days
  description: Phase I: Dose Escalation Pharmacokinetic parameters: Cmin,ss
  measure: Phase II: To evaluate the safety and tolerability of TCC1727 tablets in patients with advanced solid tumors with DDR defects
  time frame: 6 months
  description: Phase II: Cohort Expansion Assessment of all AEs, SAEs and TEAEs;
  arm group label: 5mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  arm group label: 10mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  arm group label: 20mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  arm group label: 40mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  arm group label: 60mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  arm group label: 80mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  arm group label: 100mg treatment group
  arm group type: Experimental
  description: Administered orally once a day (QD)
  intervention type: Drug
  intervention name: TCC1727 tablet
  description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
  arm group label: 100mg treatment group
  arm group label: 10mg treatment group
  arm group label: 20mg treatment group
  arm group label: 40mg treatment group
  arm group label: 5mg treatment group
  arm group label: 60mg treatment group
  arm group label: 80mg treatment group
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 70 Years
  healthy volunteers: No
  last name: Lingying Wu, PHD
  phone: 86-01-87788996
  email: wulingying@csco.org.cn
  last name: Guangwen Yuan, PHD
  phone: 86-01-87788996
  email: william327@126.com
  facility: 
  contact: 
  contact backup: 
  country: China
  responsible party type: Sponsor
  mesh term: Neoplasms
  sharing ipd: No